Ali Alhammad

Experience

• 

  Aramco

  May 1999 - Aug 1999

  Pharmacy Summer Intern

  • Trained at different areas of pharmacy• Attended many intensive rotations in 4 different medical wards• Wrote two issues of the pharmacy newsletter• Excellent performance award

• 

  Aramco

  May 2000 - Aug 2000

  Pharmacy Summer Intern

  • Trained at different areas of pharmacy• Attended many intensive rotations in 4 different medical wards• Wrote two issues of the pharmacy newsletter• Excellent performance award

• 

  King Fahd Military Medical Complex (KFMMC)

  Aug 2000 - Mar 2006

  • Occupied some administrative duties including inpatient supervisor and outpatient supervisor• Chairman of the infection control committee (2004 – 2006)• Member of the organizing committee for the 3rd International Pharmaceutical Conference at KFMMC, 2005

  • Senior Hospital Pharmacist

    Aug 2003 - Mar 2006

  • Hospital Pharmacist

    Aug 2000 - Aug 2003
• 

  Virginia Commonwealth University

  Jan 2011 - Dec 2011

  Graduate Teaching Assistant

  Teaching PharmD students

• 

  Abbott

  Jan 2012 - Sept 2012

  Health Economincs and Outcome Research Manager

  I worked on several projects including:• Responsible for HTA dossier and access strategy of childhood vaccine • Deep analysis of Saudi Arabian healthcare system to localize the global dossier and market access solutions to KSA settings• Deep analysis of Colombian healthcare system to localize the global dossier and market access solutions to Colombian settings

• 

  Ministry of National Guard Health Affairs (MNGHA)

  Jan 2013 - Dec 2017

  Pharmacoeconomics and Health Outcomes Consultant

  • Established the main health technology assessment framework and developed the forms and guidelines used by the Drug Policy and Economic Center.• Lead a team of pharmacoeconomists in three main therapeutic areas (oncology, infectious disease, and other medications) • Conducting medication appraisals for all new formulary addition requests - 13 oncology appraisals - 4 antimicrobials appraisals - 48 other medications appraisals• Developing pharmacoeconomics models and Drug Evaluations for formulary decision-making, drug policy, and drug use guideline development for all formulary addition requests at the NGHA• Main deliverables: - Cost-effectiveness analysis and Budget-Impact analysis - Outcome assessment using EMR data for drug utilization reviews - Drug Utilization Review (DURs) and Drug Use Evaluations (DUEs) - Policy development - Drug policy analysis - Annual Pharmaceuticals Expenditures Reports• Active member of the several committees, subcommittees, task forces, and initiatives عرض أقل

• 

  IMS Health

  Jan 2015 - Jan 2018

  External Senior Consultant Pharmacoeconomics and Health Outcome

  The team leader in several local projects in the Gulf countries for several multinational pharmaceutical companies• Global model adaptation• Local cost estimations• Real-world data collection and analysis

• 

  Eli Lilly and Company

  Jan 2019 - Nov 2021

  • Currently, I'm the Market Access and Real-World Evidence (RWE) Lead at Eli Lilly and Company, Riyadh, Saudi Arabia. • Responsible for developing strategies and solutions for Lilly’s products pre- and post-launch studies to fill the local evidence gaps and support the value proposition of Lilly products in the Saudi market, such as: - prospective and retrospective studies - registry data analyses - meta-analysis and network meta-analysis - local pharmacoeconomic• Focus areas are: - Diabetes and connected care - Immunology; primarily dermatology and Rheumatic disease - Pain; primarily headache and migraine - Oncology; primarily breast cancer and colorectal cancer • These solutions are developed jointly with medical, market access, PRA, and sales teams as well as the brand managers• These solutions are also co-created with local HCPs, payers, and decision-makers in top institutions and MoH to understand gaps from customers perspectives and provide the right tools to help them make an informed decision• Alignment with the global team on the global brand strategies• The medical and business backgrounds, long experience in market access, health economics and RWE, and deep understanding of Saudi Arabia healthcare system, provided the needed tools for a strategic brand and customer planning for successful launches and access of Lilly brands resulted in several successful formulary listing of our brands in MoH and other institutions. عرض أقل

  • Market Access and Real-World Evidence Lead

    Sept 2017 - Nov 2021

  • Qualified Person Responsible For Pharmacovigilance (QPPV) Back-Up

    Jan 2019 - Jan 2021
• 

  GSK

  Nov 2021 - now

  Value Generation & Medical Access Lead

  My role is to ensure quick patients access to GSK medications based on solid science/evidence via the development and implementation of Local Health Outcomes evidence strategies/plans for GSK products to support commercialization pre/post-launch, and throughout the life cycle in Saudi Arabia.My main functions are:1. Access-Evidence Planning2. Value Dossiers3. Health Economic Models4. Epidemiology Studies5. Customer Engagement